Product Images Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate And Amphetamine Sulfate

This is a medication information for extended-release capsules containing Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate (mixed salts of a single-entity Amphetamine product). It is prescribed medication and comes in a container of 30 capsules. The pharmacist needs to dispense a medication guide to each patient. The medication needs to be kept in tight, light-resistant containers at controlled room temperatures. Each extended-release capsule contains a certain quantity of the above-mentioned ingredients. The manufacturer is Ascent Pharmaceuticals.*

This is a description of a medication called Dextroamphetamine Saccharae and Amphetamine Aspartate Monohydrate. The medication comes in the form of extended-release capsules and is a single-entity amphetamine product, made up of a mixture of salts. It is important for the pharmacist to dispense the medication guide to each patient. The medication should be stored at a temperature between 20° and 25°C, with excursions permitted between 15° and 30°C. Tight, light-resistant containers must be used, and the package insert should be consulted for complete information. Each capsule contains Dextroamphetamine Saccharate 2.5 mg, Amphetamine Aspartate Monohydrate 2.5 mg, Dextroamphetamine Sulfate, USP 2.5 mg, and Amphetamine Sulfate, USP 2.5 mg. The total amphetamine base equivalence is 6.3 mg. The medication is manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY.*

This is a medication contained in a bottle of 30 extended-release capsules. The medication contains four mixed salts of a single-entity amphetamine product, which are Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate. Each capsule contains 3.75 mg of each salt, with a total equivalent of 9.4 mg of amphetamine base. The medication guide must be provided to each patient when it is being dispensed. It must be stored in airtight and dark containers defined in the USP, at the temperature of 20° to 25°C, with some excursions permitted. It is manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY 11722.*

This is the description of a prescription medication named "Dextroamphetamine Saccharae, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate," which contains extended-release capsules that are to be dispensed with accompanying medication guides to patients. It comes in a container of 500 capsules and should be stored within a 20°C to 25°C temperature range. Each capsule contains Dextroamphetamine Saccharate 375 mg, Amphetamine Aspartate Monohydrate 375 mg, Dextroamphetamine Sulfate, USP 375 mg, and Amphetamine Sulfate, USP 375 mg. However, the total amphetamine base equivalence of each capsule is 9.4 mg. This medication is manufactured by Ascent Pharmaceuticals, Inc., located in Central Islip, NY.*

It is a description of a medication called 0E6LE | ZOIEY. It is a single-entity amphetamine product that comes in extended-release capsules of 20 mg. The medication contains Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate (mixed salts). The pharmacist needs to dispense the medication guide to each patient, and it should be stored in a tight, light-resistant container at the USP-controlled room temperature. Each capsule contains 12.5 mg of total amphetamine base equivalence. It is manufactured by Ascent Pharmaceuticals, Inc in Central Islip, NY.*

This is a medication called NDC 43602-319-05, which is a single-entity amphetamine product made of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate, packaged in extended-release capsules. The medication should be stored within the temperature range of 20° to 25°C (68° to 77°F) with some allowance for excursions within 15° to 30°C (59° to 86°F). It should be kept in a tightly closed, light-resistant container. Each capsule contains a total of 12.5 mg of amphetamine base equivalence, with 5 mg of each of the four active ingredients. The manufacturer is Ascent Pharmaceuticals, Inc based in Central Islip, NY. A medication guide should be dispensed to the patient by the pharmacist.*

This is a description of a medication labeled as an extended-release capsule containing a mixture of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate. The medication is manufactured by Ascent Pharmaceuticals, Inc. and each capsule contains a total of 15.6 mg of amphetamine base equivalence. The medication requires a prescription and should be stored in a tight, light-resistant container at a controlled temperature between 20° and 25°C. Pharmacist should dispense the Medication Guide to each patient. For more information refer to the package insert.*

This is a medication guide for Dextroamphetamine Saccharate and Amphetamine Aspartate Monohydrate in Extended-Release Capsules. The medication contains a mixture of single-entity amphetamine salts. The pharmacist should dispense the medication guide to each patient. The medication should be stored in a tight, light-resistant container at a temperature between 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). Each extended-release capsule contains specific quantities of the drugs mentioned. The manufacturer of the medication is Ascent Pharmaceuticals, Tnc, located in Central Tslip, NY 11722.*

This is a description for a medication called "it" which has errors and is not available.*

This is a medication that comes in the form of extended-release capsules containing four salts of amphetamine. Each capsule includes four active ingredients: Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, which in total provide 18.8mg of amphetamine base equivalence. This medication is recommended to be stored at temperature ranging from 20°C to 25°C (68°F to 77°F) and it is manufactured by Ascent Pharmaceuticals Inc. It is necessary to dispense this medication with a medication guide for each patient, in a tight light-resistant container, and under USP controlled room temperature.*

This is a product for pharmacists to dispense to patients. It contains a mix of amphetamines in extended-release capsules. The product is stored at a controlled temperature, and the accompanying Medication Guide is to be given to each patient. Tight, light-resistant packaging is required. The product is manufactured by Ascent Pharmaceuticals, Inc. Full information is available in the package insert.*

This is a prescription medication with a National Drug Code of 43602-316-05. It is an extended-release capsule that includes a mixed salt of a single-entity amphetamine product consisting of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate. Each capsule contains 125mg of the Dextroamphetamine Saccharate, 125mg of the Amphetamine Aspartate Monohydrate, 125mg of the Dextroamphetamine Sulfate, and 125mg of the Amphetamine Sulfate, which equates to 3.1mg total amphetamine base equivalence. The medication guide must be dispensed with the capsules, and they should be stored in a tight, light-resistant container at a temperature of 20° to 25°C. The manufacturer is Ascent Pharmaceuticals, Inc, located in Central Islip, NY.*

This is a dataset consisting of mean plasma concentrations of two types of amphetamines (dextro and levo) over a period of 30 hours. The concentrations are measured in ngimd. The data points are provided at various time intervals ranging from 12 to 30 hours.*

Table 1 shows the adverse reactions reported in a clinical study of 584 children aged 6-12 years who received Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules. The table shows adverse reactions with an incidence higher than placebo and a frequency of 2% or more. These include general abdominal pain, fever, infection, accidental injury, asthenia, loss of appetite, vomiting, nausea, dyspepsia, insomnia, emotional lability, nervousness, dizziness, and weight loss.*

This is a table showing the adverse reactions reported by adolescents (13-17 years of age) who weigh less than 75 kg/165 Ibs and were receiving Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate. These capsules have been used in a clinical study where 287 patients underwent weekly-dose titration. The table shows the body system preferred term, and the percentage of patients who experienced these reactions under test conditions and, in some cases, placebo conditions. In total, five adverse reactions, including abdominal pain, loss of appetite, insomnia, nervousness, and weight loss had a higher occurrence rate in the test group than the placebo group. Other reactions are also mentioned in the table, but they did not meet the rate criteria for inclusion in Table 2.*

Table 3 provides a breakdown of the adverse reactions reported by 5% or more of adults who took Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules over a placebo in a 255 patient clinical study. This table also indicates that certain reactions, such as headache, dry mouth, loss of appetite, and insomnia, were more frequently reported by those using the medication. The table also lists less common but still reported reactions by 2-4% of adult patients taking the medication, including infection and emotional lability.*

This text provides warnings and potential interactions for medications containing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. Concomitant use with certain medications, such as monoamine oxidase inhibitors, serotonin reuptake inhibitors, and alkalinizing agents, can cause adverse reactions and should be avoided. Tricyclic antidepressants and proton pump inhibitors may enhance or decrease the activity or effectiveness of the amphetamine capsules, and their use with caution is recommended.*